The Angiogenesis Library available for research contains a collection of 17,000 compounds that focus on targeting the process of angiogenesis. Angiogenesis is a crucial physiological process that involves the formation of new blood vessels from pre-existing ones. It is responsible for the continued growth of the vasculature through mechanisms such as sprouting and splitting.
During embryonic development, vasculogenesis occurs, which involves the formation of endothelial cells from mesodermal cell precursors and neovascularization. After this initial stage, angiogenesis takes over as the primary driver of blood vessel growth, both in normal growth and development and in various disease processes.
While angiogenesis is essential for normal processes such as growth, wound healing, and the formation of granulation tissue, it also plays a significant role in the progression of tumors from a benign to a malignant state. This makes targeting angiogenesis a crucial strategy in cancer treatment, leading to the development of angiogenesis inhibitors.
The targets included in the Angiogenesis Library encompass a range of important signaling pathways involved in angiogenesis. These targets include VEGFR (vascular endothelial growth factor receptor), FGFR (fibroblast growth factor receptor), PDGFR (platelet-derived growth factor receptor), EGFR (epidermal growth factor receptor), FLT3 (Fms-like tyrosine kinase 3), FAK (focal adhesion kinase), JAK-1,2 (Janus kinase 1 and 2), TIE-1,2 (tyrosine kinase with immunoglobulin-like and EGF-like domains 1 and 2).
By providing access to a diverse array of compounds targeting multiple key players in angiogenesis, the library offers researchers valuable resources to study and develop potential therapies for various angiogenesis-related conditions, including cancer.
